港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

醫美概念股

860.685

-4.364-0.50%

漲家數：3

跌家數：6

平家數：4

市盈率：- -

高：881.520

開：863.928

低：841.556

收：865.049

成交量：5,559.26萬

成交額：3.95億

市值：1,441.24億

流通市值：1,046.69億

資料載入中...

總覽新聞資訊

醫美概念股局部走高四環醫藥（00460）漲2.53% 機構指行業結構性機會持續存在

【券商聚焦】中信證券：美妝行業普遍面臨收入和純利率兩個維度的壓力

【券商聚焦】中信建投醫療器械和服務2027年投資策略：板塊性機會逐漸顯現

復鋭醫療科技(01696.HK)11月5日斥資約2.9萬港元回購1.6萬股

瑞麗醫美(02135)股價下跌9.804%，現價港幣$0.092

阿斯达克财经

港股異動 | 康哲藥業(00867)升逾4% 創新藥磷酸蘆可替尼乳膏新加坡上市許可申請獲批

【券商聚焦】國泰海通證券：美護板塊估值及持倉均處底位，看好成長型標的修復彈性

完美醫療(01830.HK)擬11月16日舉行董事會會議審批中期業績

復鋭醫療科技(01696)11月4日斥資約9.04萬港元回購5萬股

麗豐控股(01125.HK)：公眾持股量為14.76%

復星醫藥(02196)：FXS6837膠囊用於治療陣發性睡眠性血紅蛋白尿症於中國境內1啓動III期臨床試驗

復星醫藥(600196.SH)子公司HLX109注射液獲准於澳大利亞開展臨床試驗

【灣區早參】香港第三季本地生產總值較上年同期實質上升5.2%；澳門9月居民存款按月跌1.1%

康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏新加坡上市許可申請獲批

康哲藥業：Rxilient Medical於2026年11月3日獲HSA批准磷酸蘆可替尼乳膏新藥上市申請

三生製藥10月回購633.75萬股持作庫存股份

復鋭醫療科技(01696.HK)11月2日斥資9.13萬港元回購5萬股

昊海生物科技(06826)11月2日斥資約74.08萬港元回購4.6萬股

復星醫藥(02196.HK)：袁方兵辭任副總裁

復星醫藥(02196.HK)11月2日耗資約3332.37萬港元回購200萬股

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/BK1593/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"醫美概念股","latestPrice":860.68463,"timestamp":1793952530468,"preClose":865.0486,"halted":0,"volume":55592590,"delay":0,"changeRate":-0.005045,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-4.363953,"latestTime":"11-06 16:00:00","open":863.9281,"high":881.51965,"low":841.5564,"amount":395187575.5,"amplitude":0.046198,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"pbRate":1.11105,"peRate":10.148077,"turnoverRate":0.002705,"increases":3,"decrements":7,"flats":3,"marketCap":144123646896,"floatMarketCap":104669312304},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":881.51965,"amplitude":0.046198,"preClose":865.0486,"low":841.5564,"pbRate":"1.11105","latestPrice":860.68463,"volume":55592590,"delay":0,"open":863.9281,"prevYearClose":1094.978,"prevWeekClose":798.351,"prevMonthClose":798.351,"prevQuarterClose":907.15,"fiveDayClose":798.351,"twentyDayClose":856.485,"sixtyDayClose":956.832,"secType":"PLATE","market":"HK","turnoverRate":0.002705,"peRate":10.148077,"marketCap":144123646896,"floatMarketCap":104669312304,"timestamp":1793952530468,"nameCN":"醫美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":3,"down":6,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2681880484","title":"醫美概念股局部走高 四環醫藥（00460）漲2.53% 機構指行業結構性機會持續存在","url":"https://stock-news.laohu8.com/highlight/detail?id=2681880484","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681880484?lang=zh_tw&edition=fundamental","pubTime":"2026-11-06 10:05","pubTimestamp":1793930738,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医美概念股局部走高，截至发稿，四环医药（00460）涨2.53%，美丽田园医疗健康（02373）涨1.99%，时代天使（06699）涨2.00%，三生制药（01530）涨1.69%，康哲药业（00867）涨1.61%。消息面上，中信证券研究指，医美行业当前处于上游注册证快速增加的阶段，竞争较为激烈，但结构性机会持续存在：差异化新品红利仍存，营销获客、医学推广、产品组合、渠道运营等综合能力强的上游品牌有望在竞争中胜出。下游显著受益于产业链格局变化，能够夯实自身美誉度、降低获客成本以及提供综合解决方案、提升毛利率的下游品牌有望持续提升份额。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995397","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","BK1100","02373","SG9999015952.SGD","IE00BVYPNQ40.USD","SG9999015978.USD","00867","BK1191","BK1593","BK1215","BK1600","IE00BGHQDM52.EUR","IE00BYV24P56.USD","BK1161","BK1515","01530","00460","SG9999015986.USD","IE00BMCWC346.EUR","SG9999015945.SGD","SG9999004311.SGD","BK1583","06699","IE00BVYPNP33.GBP","HK0000165453.HKD","BK1587","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681188245","title":"【券商聚焦】中信證券：美妝行業普遍面臨收入和純利率兩個維度的壓力","url":"https://stock-news.laohu8.com/highlight/detail?id=2681188245","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681188245?lang=zh_tw&edition=fundamental","pubTime":"2026-11-06 09:04","pubTimestamp":1793927073,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，美妆板块在需求疲弱、线上运营成本上升、竞争持续高压的环境下，当前普遍面临收入和净利率两个维度的压力。各上市美妆公司的品牌/产品/渠道/公司治理等方面的差异决定了各自所处阶段的不同，当前快速成长期公司稀缺，低谷修复期公司增多。展望未来，头部企业主品牌有望陆续恢复增长，并通过多品牌、多品类、多领域、集团化等举措建立第二成长曲线，奠定下一阶段增长基础。风险提示：居民购买力或不达预期；流量和营销费用激增侵蚀净利率；美妆存量整合，竞争失序侵蚀业绩；医美对美妆产生结构性冲击；各公司布局多品牌、多品类导致管理难度加大，进而冲击业绩；政策监管超预期；重大舆情等黑天鹅事件等。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995362","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1516","LU1580142542.USD","BK0183","LU1720050803.USD","LU1997245094.SGD","LU1997245177.USD","BK0188","BK1215","LU1794554557.SGD","LU2495084118.USD","BK1521","LU0502904849.HKD","LU1146622755.USD","LU2148510915.USD","SG9999004311.SGD","BK0012","LU0455707207.USD","LU1064131003.USD","BK0196","06030","ZBmain","BK0276","600030","LU0405327494.USD","02367","LU1328615791.USD","BK1207","BK1147","BK0028","BK1564","LU2488822045.USD","LU2289578879.USD","ZTmain","LU0405327148.USD","01830","02145","LU1781817850.SGD","TNmain","LU1820825898.SGD","LU2242644610.SGD","LU2580892789.USD","UBmain","LU1255011170.USD","ZFmain","BK1593","ZNmain","LU1997244956.HKD","LU2580892862.HKD","LU1655091616.SGD","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681884015","title":"【券商聚焦】中信建投醫療器械和服務2027年投資策略：板塊性機會逐漸顯現","url":"https://stock-news.laohu8.com/highlight/detail?id=2681884015","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681884015?lang=zh_tw&edition=fundamental","pubTime":"2026-11-06 08:57","pubTimestamp":1793926643,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，Q3多家公司业绩超预期、27年有望业绩改善，板块效应将逐步体现。重点关注2027年业绩增长及持续改善的公司，未来有望实现业绩估值双击。预计多个高值耗材和IVD板块的集采及降价政策影响将于年底或明年初逐步出清，板块性投资机会逐步凸显。医疗器械板块具有全球竞争力的改进式创新、突破式创新的产品正在被逐步认可，也有一批公司积极战略拓展第二增长曲线、实现海外业务高增长，估值迎来上涨。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDEV","GDOC","LU0173614495.USD","159883","IEIH","BK1571","MEDX","601066","BK1574","RSPH","BK1515","BK1610","AGNG","BK1593","BK0276","LGHT","PTH","02252","BK1247","HK0000165453.HKD","BK1142","BK1600","LNGR","BK1583","06826","BK1589","LU0287142896.SGD","HART","BK1587","BK1100","00241","BK1189","00853","BK1584","BK1585","BK1222","BK1501","02235","BK1502","09996","BK1591","01302","BK1617","BK1161","02190","01066","KCE","BK1615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681231240","title":"復鋭醫療科技(01696.HK)11月5日斥資約2.9萬港元回購1.6萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681231240","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681231240?lang=zh_tw&edition=fundamental","pubTime":"2026-11-05 18:44","pubTimestamp":1793875495,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1100","BK1585","01696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681014946","title":"瑞麗醫美(02135)股價下跌9.804%，現價港幣$0.092","url":"https://stock-news.laohu8.com/highlight/detail?id=2681014946","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681014946?lang=zh_tw&edition=fundamental","pubTime":"2026-11-05 13:24","pubTimestamp":1793856240,"startTime":"0","endTime":"0","summary":"[下跌股]瑞丽医美(02135) 股价在下午01:24比前收市价下跌9.804%，现股价为港币$0.092。至目前为止，今日最高价为$0.101，而最低价为$0.092。总成交量为51万股，总成交金额为港币$4.933万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260929144020099_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260929144020099_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2611054575/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2611054575/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1209","BK1593","02135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681015267","title":"港股異動 | 康哲藥業(00867)升逾4% 創新藥磷酸蘆可替尼乳膏新加坡上市許可申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2681015267","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681015267?lang=zh_tw&edition=fundamental","pubTime":"2026-11-05 11:04","pubTimestamp":1793847866,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康哲药业涨超4%，截至发稿，涨4.24%，报10.57港元，成交额1092.92万港元。消息面上，11月4日，康哲药业发布公告，集团附属公司RxilientMedical于2026年11月3日获得新加坡卫生科学局批准磷酸芦可替尼乳膏新药上市许可申请。本次获批，填补了新加坡白癜风治疗领域存在的空白。据悉，康哲药业自2022年起启动“产业国际化”战略，以新加坡为新兴市场业务枢纽，构筑“研、产、销”全产业链高效协同的价值闭环。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","IE00BVYPNQ40.USD","SG9999015945.SGD","BK1574","MEDX","00867","STmain","SG9999004311.SGD","IE00BGHQDM52.EUR","SG9999015986.USD","BK1161","VXUS","SG9999015978.USD","06978","BK4585","BK4588","SG9999015952.SGD","IE00BYV24P56.USD","LNGR","SG9999004220.SGD","LU2488822045.USD","KCAI","BK1191","BK1593","IPOS","IE00BMCWC346.EUR","159992","IE00BVYPNP33.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681090186","title":"【券商聚焦】國泰海通證券：美護板塊估值及持倉均處底位，看好成長型標的修復彈性","url":"https://stock-news.laohu8.com/highlight/detail?id=2681090186","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681090186?lang=zh_tw&edition=fundamental","pubTime":"2026-11-05 09:06","pubTimestamp":1793840817,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国泰海通证券研究指，26Q3美护板块收入/归母/扣非同比+10%/-36%/-29%，细分板块中个护稳健，美妆高端好于大众，医美下游好于上游，当前板块估值及持仓均处底位，看好成长型标的修复弹性。该机构推荐：1）基本面强劲的高成长标的；2）估值较低的龙头标的；3）预期低位、后续边际有望改善的标的。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995267","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","02196","BK1564","HK0000165453.HKD","BK1593","LU0502904849.HKD","BK0188","LU2488822045.USD","00460","BK0276","BK1215","SG9999004311.SGD","BK1585","BK0201","BK1100","LU2242644610.SGD","BK1191","BK1161","601211","BK1515","BK0183","BK1511","BK0012","02367","02138","01696","02611","161027","06699","02145","BK1600","KCE","02373","BK0028","BK1207","BK0184","01830","01530","BK1147","LU0455707207.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680145037","title":"完美醫療(01830.HK)擬11月16日舉行董事會會議審批中期業績","url":"https://stock-news.laohu8.com/highlight/detail?id=2680145037","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680145037?lang=zh_tw&edition=fundamental","pubTime":"2026-11-04 18:58","pubTimestamp":1793789885,"startTime":"0","endTime":"0","summary":"格隆汇11月4日丨完美医疗(01830.HK)宣布，公司将于2026年11月16日(星期一)举行董事会会议，藉以(其中包括)批准及刊发公司及其附属公司截至2026年9月30日止六个月之中期业绩，以及考虑派付中期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261104/32415776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1215","01830","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680032651","title":"復鋭醫療科技(01696)11月4日斥資約9.04萬港元回購5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680032651","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680032651?lang=zh_tw&edition=fundamental","pubTime":"2026-11-04 18:44","pubTimestamp":1793789072,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复锐医疗科技(01696)发布公告，于2026年11月4日该公司斥资约9.04万港元回购5万股，回购价格为每股1.77至1.82港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01696","BK1593","BK1585","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680031550","title":"麗豐控股(01125.HK)：公眾持股量為14.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680031550","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680031550?lang=zh_tw&edition=fundamental","pubTime":"2026-11-04 17:53","pubTimestamp":1793785987,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","01125","BK1240"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680903138","title":"復星醫藥(02196)：FXS6837膠囊用於治療陣發性睡眠性血紅蛋白尿症於中國境內1啓動III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2680903138","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680903138?lang=zh_tw&edition=fundamental","pubTime":"2026-11-04 17:49","pubTimestamp":1793785787,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，近日，上海复星医药(集团)股份有限公司(以下简称“本公司”)控股子公司上海复星医药产业发展有限公司就FXS6837胶囊(原项目代号：XH-S003，以下简称“FXS6837”)用于治疗阵发性睡眠性血红蛋白尿症于中国境内1启动III期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","BMED","BK1593","BK1191","02196","BK0183","PSYK","BK1515","BK0028","IBBJ","BK0060","BK0012","IBBQ","BK0187","BK0196","600196","BK0096","BK0239","BK0175","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680035097","title":"復星醫藥(600196.SH)子公司HLX109注射液獲准於澳大利亞開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2680035097","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680035097?lang=zh_tw&edition=fundamental","pubTime":"2026-11-04 17:08","pubTimestamp":1793783301,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)自主研发的HLX109注射液(即靶向IL1RAP的单克隆抗体)用于泛发性脓疱型银屑病治疗的I期临床试验方案获相关人类研究伦理委员会批准、并通过澳大利亚药品管理局备案，系该药品于全球范围内取得的首个临床试验许可。复宏汉霖拟于条件具备后于澳大利亚开展该药品的相关临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0183","PSYK","IBBQ","BK1191","BK0175","BK0096","BK0239","BK0012","02196","BK0196","BK0188","MDTX","BK0060","IBBJ","600196","BK0028","BK1593","BMED","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680670117","title":"【灣區早參】香港第三季本地生產總值較上年同期實質上升5.2%；澳門9月居民存款按月跌1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680670117","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680670117?lang=zh_tw&edition=fundamental","pubTime":"2026-11-04 08:34","pubTimestamp":1793752467,"startTime":"0","endTime":"0","summary":"根据预先估计数字，2026年第三季本地生产总值较上年同期实质上升5.2%，而第二季的升幅为4.2%。居民存款按月下跌1.1%至8,363亿澳门元，非居民存款减少5.9%至3,550亿澳门元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995148","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU2488822045.USD","LU0650527681.SGD","09987","LU0594300419.USD","LU0310800379.SGD","LU0348825331.USD","LU0417516902.SGD","LU0823426308.USD","LU0823426480.USD","SG9999015986.USD","IE00BGHQDM52.EUR","LU2279701549.SGD","BK1103","IE00BVYPNQ40.USD","SG9999015945.SGD","06731","BK1233","IE00BVYPNP33.GBP","SG9999002950.SGD","IE00BMCWC346.EUR","00867","SG9999004311.SGD","SG9999015978.USD","IE0034224299.USD","LU0128525929.USD","SG9999004220.SGD","LU1267930573.SGD","BK1183","BK1588","SG9999015952.SGD","LU0228659784.USD","LU0029864427.USD","LU0708994859.HKD","BK1593","02510","IE00BYV24P56.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680705943","title":"康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏新加坡上市許可申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2680705943","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680705943?lang=zh_tw&edition=fundamental","pubTime":"2026-11-04 06:37","pubTimestamp":1793745434,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，集团附属公司RxilientMedical于2026年11月3日获得新加坡卫生科学局批准磷酸芦可替尼乳膏新药上市许可申请。本次获批，填补了新加坡白癜风治疗领域存在的空白。除新加坡外，截至目前Rxilient Medical已推动Lumirix于香港特别行政区、澳门特别行政区及台湾地区正式启动销售。康哲药业自2022年起启动“产业国际化”战略，以新加坡为新兴市场业务枢纽，构筑“研、产、销”全产业链高效协同的价值闭环。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BVYPNQ40.USD","BK1574","IE00BMCWC346.EUR","IBBQ","IE00BYV24P56.USD","06978","LNGR","LU2488822045.USD","SG9999015986.USD","SG9999004311.SGD","SG9999004220.SGD","SG9999015978.USD","STmain","BK1593","SG9999015952.SGD","159992","BK1161","IE00BGHQDM52.EUR","00867","IE00BVYPNP33.GBP","BK1191","SG9999015945.SGD","IPOS","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139043846","title":"康哲藥業：Rxilient Medical於2026年11月3日獲HSA批准磷酸蘆可替尼乳膏新藥上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1139043846","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139043846?lang=zh_tw&edition=fundamental","pubTime":"2026-11-04 06:11","pubTimestamp":1793743868,"startTime":"0","endTime":"0","summary":"康哲药业宣布，Rxilient Medical于2026年11月3日获得HSA对磷酸芦可替尼乳膏新药上市申请的批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNQ40.USD","IE00BGHQDM52.EUR","IE00BYV24P56.USD","SG9999004311.SGD","SG9999015952.SGD","SG9999015945.SGD","BK1191","SG9999004220.SGD","00867","IE00BVYPNP33.GBP","IE00BMCWC346.EUR","LU2488822045.USD","BK1593","SG9999015978.USD","SG9999015986.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680575445","title":"三生製藥10月回購633.75萬股持作庫存股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2680575445","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680575445?lang=zh_tw&edition=fundamental","pubTime":"2026-11-02 19:36","pubTimestamp":1793619360,"startTime":"0","endTime":"0","summary":"11月2日，三生制药(01530.HK)公告，于2026年11月2日向香港联交所提交截至2026年10月31日止月份的证券变动月报表。2026年10月8日至14日期间，公司经2026年6月25日股东大会批准，分五次回购股份并持作库存股份，价格介于每股14.4港元至15.59港元，合计回购633.75万股。同期，公司购股权计划项下期权被行使，涉及新股66万股，行使价为每股7.62港元，所得资金总额为502.92万港元。截至2026年10月底，公司已发行股份(不包括库存股份)为25.14亿股，库存股份为2511.35万股，已发行股份总数为25.39亿股。公司确认已符合适用的公众持股量最低要求。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-11-02/doc-inixiynt0423685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","HK0000165453.HKD","01530","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680565787","title":"復鋭醫療科技(01696.HK)11月2日斥資9.13萬港元回購5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680565787","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680565787?lang=zh_tw&edition=fundamental","pubTime":"2026-11-02 19:17","pubTimestamp":1793618220,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1100","BK1585","01696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680585187","title":"昊海生物科技(06826)11月2日斥資約74.08萬港元回購4.6萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680585187","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680585187?lang=zh_tw&edition=fundamental","pubTime":"2026-11-02 17:58","pubTimestamp":1793613516,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，于2026年11月2日该公司斥资约74.08万港元回购4.6万股，回购价格为每股15.9至16.12港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1161","06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680730190","title":"復星醫藥(02196.HK)：袁方兵辭任副總裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2680730190","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680730190?lang=zh_tw&edition=fundamental","pubTime":"2026-11-02 17:37","pubTimestamp":1793612270,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1593","02196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680737463","title":"復星醫藥(02196.HK)11月2日耗資約3332.37萬港元回購200萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680737463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680737463?lang=zh_tw&edition=fundamental","pubTime":"2026-11-02 17:20","pubTimestamp":1793611208,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1191","BK1515","02196"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}